Medicare officials are proposing to restrict coverage of a controversial Alzheimer's drug, Aduhelm, to participants in the federal health insurance program who are enrolled in qualifying clinical trials. In a statement, the Centers for Medicare & Medicaid Services said Tuesday that it based its proposal on an analysis of the benefits and risks of the drug, which has raised concerns about Aduhelm's high cost and efficacy. "While there may be the potential for promise with this treatment, there is also the potential for harm to patients," said Dr. Lee Fleisher, chief medical officer at CMS and director of the Center for Clinical Standards and Quality, in the statement. "This harm may range from headaches, dizziness and falls, to other potentially serious complications such as brain bleeds." The agency said will make a final decision on covering the drug by April 11. Medicare's decision on whether to pay for Aduhelm is important because it affects whether health insurers will cover the cost. The Food and Drug Administration approved Aduhelm last June, the . . . read the full article here.